Seebri® Breezhaler® (glycopyrronium bromide) is a long-acting bronchodilator with an anticholinergic effect indicated as a maintenance treatment for patients with controlled chronic obstructive pulmonary disease (COPD). Approved dosing is one 50microgram capsule daily via the Breezhaler® inhalation device.
In clinical trials, compared to placebo, glycopyrronium bromide was demonstrated to improve lung function, increase control of COPD symptoms, reduce need for reliever inhalers and therefore improve patients’ quality of life.
Seebri® has an efficacy and adverse-effect profile similar to that of Spiriva® (tiotropium). Common side effects include dry mouth, throat irritation, gastroenteritis and insomnia. It should be used with caution in patients with risk factors for angle-closure glaucoma or prostatic symptoms. Co-administration of Seebri® with other inhaled anticholinergics (i.e. tiotropium, ipratropium) is not recommended.
Please review full product information before prescribing.
- National Prescribing Service. Glycopyrronium bromide (Seebri) for chronic obstructive pulmonary disease. Medicine Update 2014; April 1.
- National Prescribing Service. Glycopyrronium bromide (Seebri) for chronic obstructive pulmonary disease. NPS Radar 2014: April 1.
- Pharmaceutical Benefits Advisory Committee. Public Summary Document: Glycopyrronium bromide, powder for inhalation, 50 microgram, Seebri®, Breezhaler® – November 2013. Canberra: Australian Government Department of Health and Ageing; 2013.
- Seebri® Breezhaler® (glycopyrronium bromide) Australian approved consumer medicine information. North Ryde: Novartis Pharmaceuticals Australia Pty Ltd. June 2014.
- Seebri® Breezhaler® (glycopyrronium bromide) Australian approved product information. North Ryde: Novartis Pharmaceuticals Australia Pty Ltd. Approved 12 November 2012, amended 26 June 2014.